‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review

Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and more potency. ADCs have been approved for several...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Saurav, Breadner, Daniel, Raphael, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137214/
https://www.ncbi.nlm.nih.gov/pubmed/37185443
http://dx.doi.org/10.3390/curroncol30040330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137214/
https://www.ncbi.nlm.nih.gov/pubmed/37185443
http://dx.doi.org/10.3390/curroncol30040330

Ejemplares similares